These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 33333252)

  • 61. The association of interleukin-6 value, interleukin inhibitors, and outcomes of patients with COVID-19 in New York City.
    Maeda T; Obata R; Rizk DO D; Kuno T
    J Med Virol; 2021 Jan; 93(1):463-471. PubMed ID: 32720702
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Tocilizumab for the Treatment of COVID-19-Induced Cytokine Storm and Acute Respiratory Distress Syndrome: A Case Series From a Rural Level 1 Trauma Center in Western Pennsylvania.
    Suresh K; Figart M; Formeck S; Mehmood T; Abdel Salam M; Bassilly D
    J Investig Med High Impact Case Rep; 2021; 9():23247096211019557. PubMed ID: 34105382
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Early use of tocilizumab in patients with severe pneumonia secondary to severe acute respiratory syndrome coronavirus 2 infection and poor prognostic criteria: Impact on mortality rate and intensive care unit admission.
    Sánchez-Rovira P; Pérez-Chica G; Ortega-Granados AL; Aguilar-García J; Díaz-Beltrán L; Gálvez-Montosa F; García-Verdejo F; Luque-Caro N; Quero-Blanco C; Fernández-Navarro M; Rodríguez-Sánchez A; Ruiz-Bailén M; Yaguez-Mateos L; Marín-Pozo JF; Sierra-Torres MI; Lacárcel-Bautista C; Duro-Ruiz GJ; Duro-Fernández MÁ; García-Alegría J; Herrero-Rodríguez C
    Medicine (Baltimore); 2021 Jul; 100(29):e26533. PubMed ID: 34398008
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Tocilizumab reduces the risk of ICU admission and mortality in patients with SARS-CoV-2 infection.
    Moreno-García E; Rico E; Albiach L; Agüero D; Ambrosioni J; Bodro M; Cardozo C; Chumbita M; De la Mora M; García-Pouton N; Garcia-Vidal C; González-Cordón A; Hernández-Meneses M; Inciarte A; Laguno M; Leal L; Linares L; Macay I; Meira F; Mensa J; Moreno A; Morata L; Puerta-Alcalde P; Rojas J; Solá M; Torres B; Torres M; Tomé A; Tuset M; Castro P; Fernández S; Nicolás JM; Almuedo-Riera A; Muñoz J; Fernandez-Pittol M; Marcos MA; Soy D; Martínez JA; García F; Soriano A
    Rev Esp Quimioter; 2021 Jun; 34(3):238-244. PubMed ID: 33829722
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Impact of dexamethasone on the incidence of ventilator-associated pneumonia in mechanically ventilated COVID-19 patients: a propensity-matched cohort study.
    Scaravilli V; Guzzardella A; Madotto F; Beltrama V; Muscatello A; Bellani G; Monti G; Greco M; Pesenti A; Bandera A; Grasselli G
    Crit Care; 2022 Jun; 26(1):176. PubMed ID: 35698155
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Therapeutic efficacy, mechanical ventilation, length of hospital stay, and mortality rate in severe COVID-19 patients treated with tocilizumab.
    Sarhan RM; Madney YM; Abou Warda AE; Boshra MS
    Int J Clin Pract; 2021 Jun; 75(6):e14079. PubMed ID: 33550688
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Outcomes of tocilizumab therapy in severe or critical COVID-19 patients: A retrospective cohort, single-centre study.
    Abdelnaby H; Aboelhassan W; Al-Jarallah M; Rajan R; Dashti R; Zhanna KD; Alsaber AR; Abd El-Aleem A; Ashry I; Abdullah M; Mahmoud Fouad A
    Trop Med Int Health; 2021 Dec; 26(12):1689-1699. PubMed ID: 34601803
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial.
    Declercq J; Van Damme KFA; De Leeuw E; Maes B; Bosteels C; Tavernier SJ; De Buyser S; Colman R; Hites M; Verschelden G; Fivez T; Moerman F; Demedts IK; Dauby N; De Schryver N; Govaerts E; Vandecasteele SJ; Van Laethem J; Anguille S; van der Hilst J; Misset B; Slabbynck H; Wittebole X; Liénart F; Legrand C; Buyse M; Stevens D; Bauters F; Seys LJM; Aegerter H; Smole U; Bosteels V; Hoste L; Naesens L; Haerynck F; Vandekerckhove L; Depuydt P; van Braeckel E; Rottey S; Peene I; Van Der Straeten C; Hulstaert F; Lambrecht BN
    Lancet Respir Med; 2021 Dec; 9(12):1427-1438. PubMed ID: 34756178
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Tocilizumab: A retrospective multi-center cohort study of critically ill patients with COVID-19.
    Villatoro Santos CR; Bhargava A; Coyle M; Szpunar S; Saravolatz LD
    Int J Clin Pharmacol Ther; 2021 Nov; 59(11):705-712. PubMed ID: 34448693
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis, first update.
    Tleyjeh IM; Kashour Z; Riaz M; Hassett L; Veiga VC; Kashour T
    Clin Microbiol Infect; 2021 Aug; 27(8):1076-1082. PubMed ID: 33915284
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Efficacy of Tocilizumab in COVID-19: Single-Center Experience.
    Kaya S; Kavak S
    Biomed Res Int; 2021; 2021():1934685. PubMed ID: 34977235
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Tocilizumab treatment in COVID-19: A prognostic study using propensity score matching.
    Güçlü ÖA; Önal U; Akalın H; Öztürk NAA; Belik HÖ; Demirdöğen E; Dilektaşlı AG; Kazak E; Ocakoğlu G; Sağlık İ; Coşkun F; Ediger D; Heper Y; Ursavaş A; Yılmaz E; Uzaslan E; Karadağ M
    Adv Clin Exp Med; 2022 Nov; 31(11):1197-1206. PubMed ID: 35951629
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Tocilizumab for the treatment of adult patients with severe COVID-19 pneumonia: A single-center cohort study.
    Fernández-Ruiz M; López-Medrano F; Pérez-Jacoiste Asín MA; Maestro de la Calle G; Bueno H; Caro-Teller JM; Catalán M; de la Calle C; García-García R; Gómez C; Laguna-Goya R; Lizasoáin M; Martínez-López J; Origüen J; Pablos JL; Ripoll M; San Juan R; Trujillo H; Lumbreras C; Aguado JM
    J Med Virol; 2021 Feb; 93(2):831-842. PubMed ID: 32672860
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Tocilizumab shortens time on mechanical ventilation and length of hospital stay in patients with severe COVID-19: a retrospective cohort study.
    Eimer J; Vesterbacka J; Svensson AK; Stojanovic B; Wagrell C; Sönnerborg A; Nowak P
    J Intern Med; 2021 Mar; 289(3):434-436. PubMed ID: 32744399
    [No Abstract]   [Full Text] [Related]  

  • 75. Tocilizumab treatment for COVID-19 patients: a systematic review and meta-analysis.
    Wei Q; Lin H; Wei RG; Chen N; He F; Zou DH; Wei JR
    Infect Dis Poverty; 2021 May; 10(1):71. PubMed ID: 34001244
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Effects of tocilizumab on mortality in hospitalized patients with COVID-19: a multicentre cohort study.
    Martínez-Sanz J; Muriel A; Ron R; Herrera S; Pérez-Molina JA; Moreno S; Serrano-Villar S
    Clin Microbiol Infect; 2021 Feb; 27(2):238-243. PubMed ID: 32979572
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Does timing of tocilizumab administration affect mortality in COVID-19? A Scottish multicentre retrospective cohort study.
    MacGregor F; Oprey A; Caulfield C; MacTavish P; Lowrie R; Henderson P
    BMJ Open Respir Res; 2024 Aug; 11(1):. PubMed ID: 39214629
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Management and outcomes of patients hospitalized with severe COVID-19 at a tertiary care center in midwestern United States.
    Gupta S; Kaushik A; Gupta J
    Monaldi Arch Chest Dis; 2020 Oct; 90(4):. PubMed ID: 33059413
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab.
    Langer-Gould A; Smith JB; Gonzales EG; Castillo RD; Figueroa JG; Ramanathan A; Li BH; Gould MK
    Int J Infect Dis; 2020 Oct; 99():291-297. PubMed ID: 32768693
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Early outcomes in adults hospitalized with severe SARS-CoV-2 infection receiving tocilizumab.
    Sánchez-Montalvá A; Sellarés-Nadal J; Espinosa-Pereiro J; Fernández-Hidalgo N; Pérez-Hoyos S; Salvador F; Durà X; Miarons M; Antón A; Eremiev-Eremiev S; Sempere-González A; Monforte-Pallarés A; Bosch-Nicolau P; Augustin S; Sampol J; Guillén-Del-Castillo A; Almirante B
    Med Clin (Barc); 2022 Jun; 158(11):509-518. PubMed ID: 34544604
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.